Leerink Cuts Hims & Hers Target After Novo Nordisk Files Semaglutide Suit
Leerink Partners trimmed its price target on Hims & Hers (NYSE: HIMS) to $20.00 from $24.00 and kept a Market Perform rating, pointing to legal uncertainty after Novo Nordisk filed a patent infringement lawsuit tied to compounded semaglutide products. The research note highlights that the contested weight-loss offerings contribute a sizable portion…